Review finds animal evidence for BCP, but human benefits remain unproven
Beta-Caryophyllene (BCP) Modulating the Endocannabinoid System and PPARγ to Combat Metabolic Dysregulation: A Narrative Review.
AI Summary
This narrative review asks whether beta-caryophyllene (BCP), a compound found in spices such as black pepper and cloves, could help address metabolic dysregulation. It synthesizes existing research, with evidence described in the abstract coming from animal studies; it does not report a new clinical trial or human study. The review focuses on proposed interactions with the endocannabinoid system and PPAR-γ, and on pathways involved in glucose and lipid regulation.
The abstract reports that animal research suggests BCP may lower blood lipids and support insulin sensitivity, while reducing oxidative stress and inflammation; it also describes changes in inflammatory cytokines and adiponectin and leptin. No quantitative results are provided, so the size of these effects cannot be assessed. The authors identify first-pass metabolism and the need for improved delivery systems as important translational hurdles. This is an abstract-based summary: a narrative review cannot establish that BCP safely or effectively treats metabolic disease in people.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More Endocannabinoid research papers you might find interesting.
Meta-analysis finds shared endocannabinoid gene changes across myopathies
Small biomarker analysis finds no significant changes after 10 HBOT sessions
Rat study finds mixed behavioral and biological effects of WIN under chronic…
Explore More Research
Stay informed about the latest cannabis science.